Level Biotechnology Market Cap ($31.08 Million)
Market Cap & Net Worth: Level Biotechnology (3118)
Level Biotechnology market cap. Level Biotechnology (TWO:3118) has a market capitalization of $31.08 Million (NT$986.57 Million) as of November 5, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #23453 globally and #1475 in its home market, demonstrating a -1.30% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Level Biotechnology's stock price NT$30.40 by its total outstanding shares 32452900 (32.45 Million). Also see Level Biotechnology (3118) cash conversion ratio for how efficiently the company converts equity into cash flow.
Level Biotechnology Market Cap History (2015–2026)
Level Biotechnology market cap history from 2015 to 2026. Data shows growth from $26.14 Million to $31.08 Million (2.15% CAGR). Check 3118 stock price for real-time trading data and today's change.
Level Biotechnology Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Level Biotechnology's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Level Biotechnology (3118) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.04x
Level Biotechnology's market cap is 0.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.50x
Level Biotechnology's market cap is 0.50 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $24.47 Million | $577.63 Million | $68.31 Million | 0.04x | 0.36x |
| 2018 | $22.67 Million | $629.03 Million | $38.91 Million | 0.04x | 0.58x |
| 2019 | $22.43 Million | $638.90 Million | $47.40 Million | 0.04x | 0.47x |
| 2020 | $25.80 Million | $672.49 Million | $58.04 Million | 0.04x | 0.44x |
| 2021 | $27.17 Million | $677.28 Million | $68.18 Million | 0.04x | 0.40x |
| 2022 | $26.76 Million | $593.01 Million | $58.47 Million | 0.05x | 0.46x |
| 2023 | $31.13 Million | $660.61 Million | $62.91 Million | 0.05x | 0.49x |
| 2024 | $32.72 Million | $731.35 Million | $64.81 Million | 0.04x | 0.50x |
Competitor Companies of 3118 by Market Capitalization
Companies near Level Biotechnology in the global market cap rankings as of November 5, 2026. Also see 3118 total asset value for a full breakdown of the balance sheet.
Key companies related to Level Biotechnology by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Level Biotechnology (2015–2026)
Market capitalization of Level Biotechnology from 2015 to today. Between 2015 and today, Level Biotechnology's market cap moved from $26.14 Million to $ 31.08 Million, with a yearly change of 2.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$31.08 Million | -7.88% |
| 2025 | NT$33.74 Million | +3.12% |
| 2024 | NT$32.72 Million | +5.09% |
| 2023 | NT$31.13 Million | +16.33% |
| 2022 | NT$26.76 Million | -1.49% |
| 2021 | NT$27.17 Million | +5.31% |
| 2020 | NT$25.80 Million | +15.05% |
| 2019 | NT$22.43 Million | -1.06% |
| 2018 | NT$22.67 Million | -7.37% |
| 2017 | NT$24.47 Million | +13.40% |
| 2016 | NT$21.58 Million | -17.45% |
| 2015 | NT$26.14 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Level Biotechnology was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $31.08 Million USD |
| MoneyControl | $31.08 Million USD |
| MarketWatch | $31.08 Million USD |
| marketcap.company | $31.08 Million USD |
| Reuters | $31.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Level Biotechnology
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. It markets and distributes biomedical precision equipment. The company also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the bio… Read more